When it was licensed for the treatment of metastatic melanoma and renal cell carcinoma in 1998, interleukin-2 (IL-2), a T-cell growth factor that aids in immunological modulation and T-cell proliferation, became the second anticancer cytokine approved by the FDA. The gene discussed is IL2; the disease is metastatic melanoma.